Related Experiment Video
Updated: Jan 3, 2026
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
[Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy]
Madoka Koyanagi1, Satoshi Imai1, Takayuki Nakagawa1
1Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
Abstract:
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect frequently caused by taxanes. Because the mechanisms underlying CIPN pathogenesis remain to be fully elucidated, there is no indicator for objective diagnosis like a biomarker. In addition, treatment options for CIPN is still unsatisfactory. We have previously demonstrated that paclitaxel preferentially impair myelin-forming Schwann cells, and consequently induce dedifferentiation and demyelination of Schwann cells. Recently, in a paclitaxel CIPN model mouse, we found that an inflammatory factor is released from dedifferentiated Schwann cells in the mouse sciatic nerve into the blood, highly correlated with the on-set of mechanical hypersensitivity. On the other hand, considering our previous findings, it seems that some drugs, which supply newly formed mature Schwann cells at the sites of demyelinated lesions, may be a new beneficial therapy for taxane-induced peripheral neuropathy. In this review, we will introduce our findings about new therapeutic drug candidate for taxane-related CIPN based on this concept, and plasma biomarker to detect CIPN on-set and progression.
Insights
Chemotherapy-induced peripheral neuropathy (CIPN) is a taxane side effect lacking biomarkers and effective treatments. New research identifies a plasma biomarker and potential Schwann cell therapies for taxane-related CIPN.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of taxane chemotherapy.
- Current understanding of CIPN pathogenesis is incomplete, lacking objective diagnostic biomarkers and satisfactory treatments.
- Paclitaxel is known to damage myelin-forming Schwann cells, leading to demyelination.
Purpose of the Study:
- To explore novel therapeutic strategies for taxane-induced peripheral neuropathy.
- To identify potential plasma biomarkers for early detection and monitoring of CIPN.
- To investigate the role of Schwann cell dedifferentiation in CIPN development.
Main Methods:
- Utilized a paclitaxel-induced CIPN mouse model.
- Investigated the release of inflammatory factors from dedifferentiated Schwann cells.
- Correlated inflammatory factor levels with mechanical hypersensitivity.
- Explored therapeutic potential of drugs promoting mature Schwann cell regeneration.
Main Results:
- Dedifferentiated Schwann cells release an inflammatory factor into the blood.
- This factor is highly correlated with the onset of mechanical hypersensitivity in CIPN models.
- Regenerative therapies targeting Schwann cells show promise for taxane-related CIPN.
Conclusions:
- An inflammatory factor released from dedifferentiated Schwann cells may serve as a plasma biomarker for CIPN.
- Therapeutic approaches focused on Schwann cell regeneration offer a potential new avenue for treating taxane-induced peripheral neuropathy.
More Related Videos
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
08:41Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
